FDA: No new safety concerns for Acadia's PD psychosis drug

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) rose $4.01 (27%) to $19.11 on Thursday, adding more than $500 million in market cap, after an FDA safety review of the company's Nuplazid pimavanserin found postmarketing safety data were consistent with the label's safety profile.

The small molecule serotonin (5-HT2A) receptor inverse agonist is approved to treat Parkinson's disease psychosis (PDP)...